Clinical TrialsSearch results
Number of results: 68732
- Recruitment status
- Title of the study
- Health Condition
- Primary sponsor
- Date of registration
Other
- To compare therapeutic effect of Glycyrrhizic Acid and H1-receptor antagonist for acute urticaria : a multicenter, prospective, single-blind, randomized controlled trial
- acute urticaria
- Yuzawa Community Medical Center
- 2008-07-17
Recruiting
- Phase 2 Clinical Trial for Newly Diagnosed Pediatric Acute Promyelocytic Leukemia: AML-P17
- Newly Diagnosed Pediatric Acute Promyelocytic Leukemia
- Yuza Yuki
- 2024-03-21
Recruiting
- TTF therapy for pediatric glioblastoma
- Glioblastoma
- Yuza Yuki
- 2021-04-01
Other
- Multicenter prospective study on effectiveness of color visual field test
- Healthy patient without ophthalmologic disease, glaucoma, early diabetic retinopathy, branch retinal vein occlusion, central retinal vein occlusion, central serous chorioretinopathy, epiretinal membrane, and macular hole
- Yuya Sato Eye Clinic
- 2017-09-25
Other
- OP-724-001 study
- Healthy volunteers
- Yuushi Haruyama
- 2023-11-05
Other
- Association between albuminuria and proteinuria in patients with lifestyle disease and chronic kidney disease
- lifestyle disease chronic kidney disease
- Yuurinkouseikai Fuji Hospital
- 2018-04-15
Other
- Cross-sectional association between the rate of persons particapating in specific health checkups and the rate of persons either demonstrating metabolic syndrome or pre-metabolic syndrome, and the number of patients with prevalent and incident chronic dialysis per unit population according to the causes of chronic kidney disease
- chronic kidney disease
- Yuurinkouseikai Fuji Hospital
- 2018-06-03
Recruiting
- Evaluation of nutritional changes in urine due to intake of health foods
- Healthy Adults
- Yuurea Co., Ltd.
- 2024-06-27
Recruiting
- Research on the development of a service that easily determines a child's nutritional status from urine
- Healthy infant
- Yuurea Co., Ltd.
- 2024-07-01
Recruiting
- Phase I study of OP-2100 in patients with relapsed or refractory high-risk myelodysplastic syndrome or high-risk chronic myelomonocytic leukemia
- Patients with MDS or CMML who are relapsed or refractory or intolerant to standard of care.
- Yuuki Nukazuka
- 2022-08-04